Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227961 · ClinicalTrials.gov registry record
PROMIS and Mobility Evaluation in Sarcoma Patients
A clinical trial of Sarcoma and Giant Cell Tumor of Bone, sponsored by University of Calgary.
- Recruiting
- Registry status
- 800
- Enrollment target
- 4
- Study locations
NCT07227961: Recruiting study of Sarcoma and Giant Cell Tumor of Bone, sponsored by University of Calgary.
NCT07227961 is a study of Sarcoma and Giant Cell Tumor of Bone that is actively recruiting participants, run by University of Calgary. The registered enrollment target is 800 participants, below the 915-participant average among 122 other Sarcoma trials with a reported enrollment target (13% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07227961, a study of Sarcoma and Giant Cell Tumor of Bone, is actively recruiting participants, sponsored by University of Calgary.
- RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this is to validate the Patient-Reported Outcomes Measurement Information System (PROMIS) in sarcoma patients undergoing surgery, and to evaluate a novel smartphone app for collecting mobility data. The goals of the study include to: 1. Validate PROMIS as a patient outcome measure in sarcoma 2. Assess the effectiveness of a novel app for administering questionnaires and collecting mobility metrics 3. Compare PROMIS scores and mobility metrics to better evaluate recovery trajectories after surgery Participants will complete PROMIS questionnaires at regularly scheduled intervals using the smartphone app. Questionnaires will be completed pre-operatively and at 6 weeks, 12 weeks, 6 months, and 12 months post-operatively. Additionally, the app will passively track mobility metrics such as daily step count, stairs climbed, and gait parameters to compare with PROMIS scores.
Primary Outcome
Number of steps
Conditions Studied
Interventions
- PROCEDURE Surgery
Study Locations (4)
Arizona
- Mayo Clinic - Phoenix
Minnesota
- Mayo Clinic - Rochester
Alberta
- Foothills Medical Centre, Arthur J Child Comprehensive Cancer Centre, University of Calgary - Calgary
Ontario
- Mount Sinai Hospital, University of Toronto - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2031-01-01 |
What NCT07227961 shows while recruiting
NCT07227961 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 915-participant average among 122 other Sarcoma trials with a reported enrollment target (13% lower).
The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Surgery is the first listed.
NCT07227961 reports a single indexed study location in Arizona, Minnesota, Alberta.
Frequently Asked Questions
What is clinical trial NCT07227961 about?
NCT07227961 is a clinical study titled "PROMIS and Mobility Evaluation in Sarcoma Patients". The goal of this is to validate the Patient-Reported Outcomes Measurement Information System (PROMIS) in sarcoma patients undergoing surgery, and to evaluate a novel smartphone app for collecting mobility data. The goals of the study include to: 1. Validate PROMIS as a patient outcome measure in sa...
What is the current status of trial NCT07227961?
This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2025-07-01. Estimated completion is 2031-01-01.
What conditions does trial NCT07227961 study?
This clinical trial studies the following conditions: Sarcoma, Giant Cell Tumor of Bone.
What interventions are being tested in trial NCT07227961?
The interventions under investigation include: Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT07227961?
This trial is sponsored by University of Calgary, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07227961 being conducted?
This trial has 4 study locations across Arizona, Minnesota, Alberta, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07227961's enrollment target sits among peer trials
800 12th of 122 higher than 111 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
RECRUITING
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Enhanced Recovery After Surgery in Extremity Sarcoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy